WHO Report Outlines Strategies for Improving Access to Blood Pressure Medications
In 2024, 1.4 billion people lived with hypertension, but only about one in five were able to manage it with medications or by addressing certain health risks, according to World Health Organization’s (WHO’s) recent report. Limited access to blood pressure treatments, along with inconsistent protocols and insufficient training for health care teams, is among the […]
Read More ›New USP Resources to Aid in Impurity Profiling of GLP-1 Agonists for Manufacturers
United States Pharmacopeia (USP) has published resources to support product quality for glucagon-like peptide-1 (GLP-1) agonists. The new resources include a set of reference standards and analytical reference materials for exenatide, liraglutide, and semaglutide to be used by pharmaceutical manufacturers. Additionally, USP has also prepared information sheets for testing the purity of products and an […]
Read More ›Over 29 Million People Affected by Health Care Data Breaches in First Half of 2025
In the first half of 2025, over 29 million individuals were affected by health care organization data breaches. For example, Yale New Haven Health System and Episource, LLC, were both victims of cyberattack incidents affecting over 5.4 million individuals each, according to The HIPAA Journal. In response to the 2024 Change Healthcare, Inc, cyberattack, which […]
Read More ›New FIP Guide Expands on Role of Pharmacists in Providing Vaccination Services
The International Pharmaceutical Federation (FIP) has published an updated version of its vaccination reference guide for pharmacists. The 2025 version of the FIP Knowledge and Skills Reference Guide for Professional Development in Vaccination Services expands on the roles of pharmacists in reducing vaccination hesitancy, improving vaccine uptake, and maintaining proper storage, handling, and distribution procedures […]
Read More ›SAMHSA Releases National Guidance for SUD Treatment Facilities and New Opioid Treatment Program Guidelines
The Substance Abuse and Mental Health Services Administration (SAMHSA) has released two key documents aimed at improving care for people with substance use disorder (SUD). The National Guidance on Essential Specialty Substance Use Disorder (SUD) Care outlines crucial services that should be available at SUD treatment facilities. This guidance is intended to help recognize treatment […]
Read More ›Guidance for Imported Fluid Products Published by ISMP
Following Food and Drug Administration’s approval of a temporary importation list for fluid products in response to Hurricane Helene, the Institute for Safe Medication Practices (ISMP) has released guidelines to help health care organizations evaluate safety and assess potential risks when using these imported products. ISMP’s Imported Fluid Product Checklist outlines factors that should be […]
Read More ›Support Pharmacists’ Mental Health; Become a Wellbeing First Champion
Initiated by the Dr. Lorna Breen Heroes’ Foundation, the Wellbeing First Champion Challenge for Pharmacy Licensing aims to remove the stigma surrounding mental health treatment so health care workers are not dissuaded from getting the help they need. Through the Wellbeing First Champion Challenge, pharmacy boards are urged to audit and change licensure applications by […]
Read More ›FDA Releases Draft Guidance on Pharmaceutical Development of Veterinary Drug Products
Food and Drug Administration (FDA) has released a new draft guidance for industry #290 (VICH GL61), Pharmaceutical Development. Developed for veterinary use, the draft guidance discusses the suggested contents for the Pharmaceutical Development section that is intended to help reviewers and investigators of animal drug products understand the product, as well as the manufacturing process […]
Read More ›FDA Issues Draft Interim Guidance Documents on Bulk Drug Substances in Compounding Under Sections 503A and 503B of FD&C Act
Food and Drug Administration (FDA) has issued two draft interim guidance documents that address the use of bulk drug substances in compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Under Section 503A of the FD&C Act, compounders can only use bulk substances that are included in the […]
Read More ›FDA Issues Final Guidance Document on Developing Monoclonal Antibodies for Treating COVID-19
Food and Drug Administration (FDA) has released a final guidance document offering recommendations to sponsors on developing monoclonal antibody products targeting SARS-CoV-2 intended to prevent or treat COVID-19. Additionally, the guidance document lists the criteria needed for FDA to issue emergency use authorizations. The Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization […]
Read More ›